机构：[1]Affiliated Dongguan Shilong People's Hospital of Southern Medical University, SSL Central Hospital of Dongguan City, Department of Clinical Pharmacy, Dongguan, Guangdong, China.[2]Southern Medical University, School of Pharmaceutical Sciences, Guangzhou, Guangdong, China.[3]Guangdong Medical University, School of Pharmacy, Dongguan, Guangdong, China.[4]Affiliated Dongguan Shilong People's Hospital of Southern Medical University, SSL Central Hospital of Dongguan City, Department of traditional Chinese medicine & Medical rehabilitation, Dongguan, Guangdong, China.[5]Affiliated Dongguan Shilong People's Hospital of Southern Medical University, SSL Central Hospital of Dongguan City, Department of Pharmacy, Dongguan, Guangdong, China.
Myocardial fibrosis is the most serious complication of viral myocarditis (VMC). This study aimed to investigate the therapeutic benefits and underlying mechanisms of lentivirus-mediated human tissue kallikrein gene transfer in myocardial fibrosis in VMC mice. We established VMC mouse model via intraperitoneal injection with Coxsackie B3 virus. The effect was then assessed after treatment with vehicle, the empty lentiviral vectors (EZ.null), and the vectors expressing hKLK1 (EZ.hKLK1) via tail vein injection for 30 days, respectively. The results showed that administering EZ.hKLK1 successfully induced hKLK1 overexpression in mouse heart. Compared with EZ.null treatment, EZ.hKLK1 administration significantly reduced the heart/weight ratio, improved cardiac function, and ameliorated myocardial inflammation in VMC mice, suggesting that hKLK1 overexpression alleviates VMC in mice. EZ.hKLK1 administration also significantly abrogated the increased myocardial collagen content, type I/III collagen ratio, TGF-β1 mRNA and protein expression in VMC mice, suggesting that hKLK1 overexpression reduces collagen accumulation and blunts TGF-β1 signaling in the hearts of VMC mice. In conclusion, our results suggest that hKLK1 alleviates myocardial fibrosis in VMC mice, possibly by downregulating TGF-β1 expression.
基金：
This work was supported by Scientific Research Project of
Traditional Chinese Medicine Bureau of Guangdong Province,
China (No. 20171273; No. 20201368); Medical Scientific
Research Foundation of Guangdong Province, China (No.
B2017033); and Dongguan Science and Technology Bureau,
China (No. 202071715024129); Medical Scientific Research
Foundation of Guangdong Province, China (No. B2022026).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2022]版：
大类|4 区医学
小类|4 区药学4 区医学：研究与实验
最新[2025]版：
大类|4 区医学
小类|4 区医学：研究与实验4 区药学
第一作者：
第一作者机构：[1]Affiliated Dongguan Shilong People's Hospital of Southern Medical University, SSL Central Hospital of Dongguan City, Department of Clinical Pharmacy, Dongguan, Guangdong, China.[2]Southern Medical University, School of Pharmaceutical Sciences, Guangzhou, Guangdong, China.[3]Guangdong Medical University, School of Pharmacy, Dongguan, Guangdong, China.[*1]Affiliated Dongguan Shilong People’s Hospital of Southern Medical University, SSL Central Hospital of Dongguan City, Department of Clinical Pharmacy, Dongguan, Guangdong, China
通讯作者：
通讯机构：[1]Affiliated Dongguan Shilong People's Hospital of Southern Medical University, SSL Central Hospital of Dongguan City, Department of Clinical Pharmacy, Dongguan, Guangdong, China.[2]Southern Medical University, School of Pharmaceutical Sciences, Guangzhou, Guangdong, China.[3]Guangdong Medical University, School of Pharmacy, Dongguan, Guangdong, China.[4]Affiliated Dongguan Shilong People's Hospital of Southern Medical University, SSL Central Hospital of Dongguan City, Department of traditional Chinese medicine & Medical rehabilitation, Dongguan, Guangdong, China.[*1]Affiliated Dongguan Shilong People’s Hospital of Southern Medical University, SSL Central Hospital of Dongguan City, Department of Clinical Pharmacy, Dongguan, Guangdong, China[*2]Affiliated Dongguan Shilong People’s Hospital of Southern Medical University, SSL Central Hospital of Dongguan City, Department of traditional Chinese medicine & Medical rehabilitation, Dongguan, Guangdong, China
推荐引用方式(GB/T 7714)：
Qin Youfa,Ye Xiaomei,Luo Ye,et al.hKLK alleviates myocardial fibrosis in mice with viral myocarditis[J].Journal of applied biomedicine.2023,21(1):15-22.doi:10.32725/jab.2023.005.
APA：
Qin Youfa,Ye Xiaomei,Luo Ye,Peng Luting,Zhou Guanghui...&Pan Chunyu.(2023).hKLK alleviates myocardial fibrosis in mice with viral myocarditis.Journal of applied biomedicine,21,(1)
MLA：
Qin Youfa,et al."hKLK alleviates myocardial fibrosis in mice with viral myocarditis".Journal of applied biomedicine 21..1(2023):15-22
